Analyst Ratings for ISIS Pharmaceuticals (ISIS)
ISIS Rating Summary
ISIS Price Target Summary
- Highest: $26.00 (Needham & Company)
- Lowest: $7.00 (Jefferies)
- Average: $14.50
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$14.50 (-36.3%)
Avg. $ Target:
$14.50 (-36.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/9/2012 | Cowen | Upgrade | Outperform (Neutral) |
N/A (N/A) |
7.67 | 22.76 | 196.74% | Details |
| 10/17/2012 | Summer Street | Downgrade | Neutral (Buy) |
N/A (N/A) |
10.27 | 22.76 | 121.62% | Details |
| 10/16/2012 | Piper Jaffray | Downgrade | Overweight (N/A) |
10.00 (18.00) |
13.15 | 22.76 | 73.08% | Details |
| 9/6/2012 | JMP Securities | New Coverage | Market Perform (N/A) |
N/A (N/A) |
14.79 | 22.76 | 53.89% | Details |
| 7/19/2012 | Jefferies » Updated 1/30/2013 |
Downgrade | Underperform (Buy) |
7.00 (6.50) |
14.03 | 22.76 | 62.22% | Details |
| 5/22/2012 | Needham & Company » Updated 6/4/2013 |
New Coverage | Buy (N/A) |
26.00 (N/A) |
9.41 | 22.76 | 141.87% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 8/7/2012 |
New Coverage | Hold (N/A) |
11.00 (9.00) |
8.57 | 22.76 | 165.58% | Details |
| 9/8/2011 | BMO Capital | New Coverage | Outperform (N/A) |
15.00 (N/A) |
7.41 | 22.76 | 207.15% | Details |
| 8/5/2010 | Collins Stewart | Downgrade | Neutral (N/A) |
N/A (N/A) |
9.43 | 22.76 | 141.36% | Details |
